Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 2Kidney Neoplasms 2Wilms Tumor 1Testicular Neoplasms 1Teratoma 1Sarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Medulloblastoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Familial ependymoma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Carboplatin 782Pemetrexed 606Cisplatin 544Paclitaxel 490pembrolizumab 462Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 255Nivolumab 244Bevacizumab 233osimertinib 177Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 131Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 83Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × PT-100 dipeptide × Clear all
NCT00243204 2007-06-08

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Point Therapeutics

Phase 3 Terminated
400 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡